Advertisement

hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?

  • Paolo Visca
  • Sheila Spada
  • Francesca Di Modugno
  • Emilio Bria
  • Isabella Sperduti
  • Barbara Antoniani
  • Gabriele Alessandrini
  • Belinda Palermo
  • Vienna Ludovini
  • Lucio Crinò
  • Francesco Facciolo
  • Michele Milella
  • Marcella Mottolese
  • Paola Nisticò
Open Access
Poster presentation

Keywords

NSCLC Patient Immune Checkpoint Lung Cancer Treatment Stage Lung Cancer Early Stage Lung Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Background

In lung cancer, reliable prognostic indicators of the risk of recurrence are still not available. Alternative splicing represents a potential biomarker of diagnosis, prognosis, invasiveness, and response to therapy in different tumors [1], including lung cancer [2].

Human MENA (hMENA) is an actin regulatory protein that modulates cell adhesion and migration [3]. We have isolated three hMENA splice variants, namely hMENA, hMENA11a and hMENAΔv6, impacting differently cell shape and function. hMENA11a expression ensures the integrity of cell-cell adhesion and is associated with an epithelial phenotype, whereas hMENAΔv6 is related to a mesenchymal invasive phenotype. The splicing of hMENA, relevant to epithelial mesenchymal transition, is also regulated by microenvironmental cues [4].

The dynamic reciprocity between tumor and stroma influences the tumor tissue architecture including the T cell localization. This, proposed as a prognostic marker [5], is a prerequisite for antitumor immune surveillance and recently the antibody blockade of immune checkpoints is a new reality in lung cancer treatment [6, 7].

Materials and methods

Pan-hMENA and specific hMENA11a Abs were tested by immunohistochemistry on duplicate TMA from 248 N0 NSCLC, and clinical factors (sex, age, histology, grading, T-size, number of resected nodes, RN) were correlated to 3-yr disease-free (DFS), cancer-specific (CSS), and overall survival (OS) using a Cox model. ROC analysis provided optimal cut-off values and model validation. A logistic equation including regression analysis coefficients was constructed to estimate individual patients’ probability (IPP) of relapse. Internal cross-validation (100 simulations with 80% of the dataset) and external validation was accomplished.

A panel of antibodies recognizing CD3, CD4, CD8, CD20 molecules has been employed for the characterization and localization of lymphocytes, by immunohistochemistry.

Results

In the series of N0 NSCLC patients (median follow-up: 36 months, range 1-96), Pan-hMENA and hMENA11a were the only biological variables displaying significant correlation with outcome(s), confirmed by the cross-validation (replication rate: 78%, 83%), with a prognostic model accuracy of 61% (standard error 0.04, p=0.0001). The subgroup of patients with High Pan-hMENA/Low hMENA11a relative expression fared significantly better than the other 3 groups (p≤0.002 for all outcomes). On the basis of the combination between this molecular hybrid variable and T-size and RN, a 3-risk class stratification model was generated, discriminating between patients at different risk of relapse, cancer-related death, and death for any cause, with a prognostic accuracy of 61% (standard error 0.03, p=0.01), according to ROC analysis and validated in an independent dataset of 133 patients.

The correlation between hMENA isoforms and the pattern of expression and localization of lymphocytes in the different groups of risk of relapse identified is under evaluation.

Conclusions

The hMENA splicing program is an early prognostic marker of NSCLC patients and may represent a surrogate marker of a permissive or not tumor microenvironment for lymphocyte recruitment.

References

  1. 1.
    Pal S, Gupta R, Davuluri RV: Alternative transcription and alternative splicing in cancer. Pharmacol Ther. 2012, 136 (3): 283-94. 10.1016/j.pharmthera.2012.08.005.CrossRefPubMedGoogle Scholar
  2. 2.
    Stallings-Mann ML, Waldmann J, Zhang Y, Miller E, Gauthier ML, Visscher DW, Downey GP, Radisky ES, Fields AP, Radisky DC: Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression. Sci Transl Med. 2012, 4 (142): 142ra95-PubMedCentralPubMedGoogle Scholar
  3. 3.
    Di Modugno F, Bronzi G, Scanlan MJ, Del Bello D, Cascioli S, Venturo I, Botti C, Nicotra MR, Mottolese M, Natali PG, Santoni A, Jager E, Nisticò P: Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer. 2004, 109 (6): 909-18. 10.1002/ijc.20094.CrossRefPubMedGoogle Scholar
  4. 4.
    Di Modugno F, Iapicca P, Boudreau A, Mottolese M, Terrenato I, Perracchio L, Carstens RP, Santoni A, Bissell MJ, Nisticò P: Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors. Proc Natl Acad Sci U S A. 2012, 109 (47): 19280-5. 10.1073/pnas.1214394109.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Fridman WH, Pagès F, Sautès-Fridman C, Galon J: The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012, 12 (4): 298-306. 10.1038/nrc3245.CrossRefPubMedGoogle Scholar
  6. 6.
    Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012, 12 (4): 252-64. 10.1038/nrc3239.CrossRefPubMedGoogle Scholar
  7. 7.
    Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012, 366 (26): 2455-65. 10.1056/NEJMoa1200694.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Visca et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Paolo Visca
    • 1
  • Sheila Spada
    • 1
  • Francesca Di Modugno
    • 1
  • Emilio Bria
    • 2
  • Isabella Sperduti
    • 1
  • Barbara Antoniani
    • 1
  • Gabriele Alessandrini
    • 1
  • Belinda Palermo
    • 1
  • Vienna Ludovini
    • 3
  • Lucio Crinò
    • 3
  • Francesco Facciolo
    • 1
  • Michele Milella
    • 1
  • Marcella Mottolese
    • 1
  • Paola Nisticò
    • 1
  1. 1.Regina Elena National Cancer InstituteRomeItaly
  2. 2.Medical Oncology, Azienda Ospedaliera Universitaria IntegrataUniversity of VeronaVeronaItaly
  3. 3.Medical OncologyS. Maria della Misericordia HospitalPerugiaItaly

Personalised recommendations